Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Reduced hepatic lipid contents and alleviated liver injury in EC-AMPK mice treated with selective COX-2 inhibitors. Wild-type and EC-AMPK mice given a high fat diet were treated with vehicle, celecoxib or nimesulide for a period of 4 weeks. At the end of treatment, parameters including body weight and circulating glucose (A), serum triglyceride and cholesterol levels (B were measured and presented as percentage comparisons against those from vehicle-treated wild-type mice. *P < 0.05 versus wild-type mice treated with vehicle; #P < 0.05 versus EC-AMPK mice treated with vehicle, n = 3-5.

    Br J Pharmacol 2014 171(2), 498-508. Celecoxib purchased from Selleck.

    Breast cancer cells, wild type (WT) or anoikis resistant (AR) variants, were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined by trypan blue exclusion (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control. Upper inset pictures: HCC38 cells in 96 well plates were treated with celecoxib (CEL 5.0 uM) and/or sildenafil (SIL, 2.0 uM). Cells were isolated after 24h and viability determined using a live-dead assay (red cells = dead; green cells = alive) (n = 3, +/- SEM) * p < 0.05 greater than corresponding value in vehicle control.

    J Cell Physiol 2014 10.1002/jcp.24843. Celecoxib purchased from Selleck.

Purity & Quality Control

Choose Selective COX Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MX;GeY5kfGmxbjDBd5NigQ>? MUOwMlEuOzBizszN M4Wz[FQ5KGh? NYjsd|VIcW6mdXPld{BKS0GPLUGg[ZhxemW|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx? NHSzOXMzPjVzM{G3Ni=>
H460 MYnGeY5kfGmxbjDBd5NigQ>? MnTTNE4yNTNyIN88US=> NIHVZm81QCCq NEXS[2lqdmS3Y3XzJGlESU1vMTDlfJBz\XO|aX;uJI9vKGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdA>? M4LFcVI3PTF|MUey
HKESC-2 NXHHTZNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWm2U5JQOjEEoN88US=> NUHGOJhGPDkEoHlCpC=> NXr5PJRye2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi MlX2NlY1PzR4OUO=
CaES-17 M4fUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\zbo0zOMLizszN NV7kO4NHPDkEoHlCpC=> NWD0SmdJe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgeIhmKEmFNUFCpJZidHWnczDv[kBwgGGuaYDsZZRqdsLi NU[4UnQ3OjZ2N{S2PVM>
HKESC-2 Mn7rRZBweHSxc3nzJGF{e2G7 MmrGNlDDqM7:TR?= NVT1V3IzPDkEoHlCpC=> M3fw[JJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NIrYOW0zPjR5NE[5Ny=>
CaES-17 NH61fWNCeG:ydH;zbZMhSXO|YYm= MVOyNOKh|ryP MnOyOFjDqGkEoB?= MVTy[YR2[2W|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz MlO5NlY1PzR4OUO=
A549 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fXPFUuOTZyIN88US=> NF\I[nQ1QMLiaNMg NUO0enVOTE2VTx?= Ml20TWM2OD1zNkOuOEDPxE1? Mo\JNlY1PjR4NEO=
HCC827 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluzOU0yPjBizszN M1fwfFQ5yqCqwrC= NXjv[WV{TE2VTx?= M3LiVGlEPTB;NkmuNkDPxE1? Mlf5NlY1PjR4NEO=
A549 NH7sNGNCeG:ydH;zbZMhSXO|YYm= MXi4NEDDvU1? M2PY[VQ5yqCqwrC= Mo\ISG1UVw>? NHnZfXRqdmS3Y3XzJIFxd3C2b4Ppdy=> MViyOlQ3PDZ2Mx?=
HCC827 NWDTSXRtSXCxcITvd4l{KEG|c3H5 NETaN2o5OCEEtV2= M{\MNlQ5yqCqwrC= M173bGROW09? NVXMd3F4cW6mdXPld{BieG:ydH;zbZM> M2DMOVI3PDZ2NkSz
SGC-7901/DDP NFjoNG5HfW6ldHnvckBCe3OjeR?= MVGxNOKhyrWP NWrXXIlyOjRiaB?= M4LHV4lvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44> MlTINlY1ODd4NUO=
SGC-7901  M3;mfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHMTmQzPMLiaNMg MVvJR|UxRTFzNT6wPEDPxE1? M3zSXVI3PDB5NkWz
SGC-7901/DDP NYThfppDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLoNlTDqGkEoB?= NXPXT|FyUUN3ME2zOU41PSEQvF2= NYHxUGUxOjZ2MEe2OVM>
SGC-7901/DDP MWrBdI9xfG:|aYOgRZN{[Xl? M{i3e|ExyqEEtV2= M4HmUVI1KGh? M2LvdIlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhid3n0bEBkcXOybHH0bY4> NIDBVo0zPjRyN{[1Ny=>
SGC-7901/DDP M3;pVWZ2dmO2aX;uJGF{e2G7 NHH3XnoyOMLiwsXN MVeyOEBp Ml2ybY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gVE1odHmlb4Dyc5RmcW5idHjyc5VocCCkbH;jb4lv\yCHUEKsJIFv\CCrbnHjeIl3[XSrbnegVGtCKGGwZDDDVmVDyqB? NEDTeFczPjRyN{[1Ny=>
SGC-7901/DDP NF;GXHBHfW6ldHnvckBCe3OjeR?= MnzuNVDDqML3TR?= MV:yOEBp NG\LbVVk[XW|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4> MYWyOlQxPzZ3Mx?=
H357 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TUWVcvPS9zMDFOwG0> NEKxZXo1QCCq M1zNfGROW09? NWXBUoNEcW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>? M4rRWFI3ODB7OEe0
TAF M2qwOmZ2dmO2aX;uJGF{e2G7 NGPZWWQyOMLiwsXN NEfJfmU4KGR? MY\h[oZm[3S|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>? MWeyOVk5PzF{Nx?=
TAF M4nuTWZ2dmO2aX;uJGF{e2G7 MYOxNOKhyrWP NXvQU4h7OzBvMUKwJI1qdg>? NET6PHBxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc> MUSyOVk5PzF{Nx?=
TAF NImzVHBHfW6ldHnvckBCe3OjeR?= Mm\6NVDDqML3TR?= MUS0PEBp MlfEbY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w NHzjNYEzPTl6N{GyOy=>
PANC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqyNE83OC9zMECg{txO NGDWVYQzPC92OD:3NkBp MoP4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Ml;2NlU6PzNyNkK=
PANC-1 M4HvTGZ2dmO2aX;uJGF{e2G7 MnPoNlAwPjBxMUCwJO69VQ>? NHHvb4QzPCCq NFHrOWdifHSnboXheJMh[2WubDDpcpZie2mxbjDhcoQhdWmpcnH0bY9vKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NXXGUJpbOjV7N{OwOlI>
HeLa  M13Z[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXWVXlxOjEEoN88UeKh NVXBUnBPOjUEoHi= NILpTIZmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= NWDkWFMxOjV5N{C0NlM>
SACC-83 M1LYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zsO|IxyqEQvF5CpC=> MXmyOOKhcA>? NH;hdohmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?= NFrl[pAzPTd5MESyNy=>
HeLa  NVq1Sm53SXCxcITvd4l{KEG|c3H5 NIeyWXUzOMLizszNxsA> MnXnNlTDqGh? MUnlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz MmPYNlU4PzB2MkO=
SACC-83 Mm\XRZBweHSxc3nzJGF{e2G7 MoO4NlDDqM7:TdMg NFjFNHkzPMLiaB?= Mlex[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> MV[yOVc4ODR{Mx?=
HeLa  NX\kU5NjTnWwY4Tpc44hSXO|YYm= NXrscnVEOjBxNECvPFAh|ryP MkLHNlTDqGh? MXL1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NV35OZR3OjV5N{C0NlM>
SACC-83 NGjrNZFHfW6ldHnvckBCe3OjeR?= Mlr2NlAwPDBxOECg{txO NEKyU2MzPMLiaB?= NWTLZYRVfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R? NETRbXkzPTd5MESyNy=>
HLCZ01 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrTeVFCOOLCk{[wxsDDvU1? MmrXOFghcA>? NFL3dGhFVVOR NEHSOGRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MnrCNlU4OjR6OUm=
HLCZ01 MmS4SpVv[3Srb36gRZN{[Xl? MYm0NOKh|ryP MmH5NlQhcA>? NXzNepJqTE2VTx?= MlvQbY5kemWjc3XzJIFk[3WvdXzheIlwdiCxZjDHNE9IOS2yaHHz[UBk\WyuczDjc41jcW6nZDD3bZRpKEmITj5OtS=> MmnDNlU4OjR6OUm=
HLCZ01 MnLkRZBweHSxc3nzJGF{e2G7 NGfFU3g1OMLizszN M3PRflI1KGh? M{iySmROW09? NUjIVnM5\W6qYX7j[ZMh[XCxcITvd4l{KGOxbXLpcoVlKHerdHigTWZPNc7z MoHDNlU4OjR6OUm=
HLCZ01 Ml7kSpVv[3Srb36gRZN{[Xl? NY\WeoVSPDEEoN88US=> MmHWNlQhcA>? NVTxVphHTE2VTx?= NFK5WmpqdmO{ZXHz[ZMhXFKDSVyg[ZhxemW|c3nvckBkd22kaX7l[EB4cXSqIFnueIVz\mW{b36t{tE> M4PmTFI2PzJ2OEm5
MGC803 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOwMVYxKM7:TR?= MWO3NkBp NUjiWm5kUUN3ME20O{4zPeLCidMx5qCKPi52MzFOwG0> MXiyOVcxOTN5OB?=
SGC7901 NGnRVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rMcFAuPjBizszN NY[1VndCPzJiaB?= MV;JR|UxRTR|LkWz5qCKyrIkgJm1MlEzKM7:TR?= NHTTSJczPTdyMUO3PC=>
MGC803 MmS1SpVv[3Srb36gRZN{[Xl? M3vtSVQxyqEQvF2= MWq4M|E3NzJ2IHi= MYX1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36= NY\G[WFkOjV5MEGzO|g>
SGC7901 MXnGeY5kfGmxbjDBd5NigQ>? Moi2OFDDqM7:TR?= M13qXFgwOTZxMkSgbC=> M3frTpVxemWpdXzheJMhS2KuLXKg[ZhxemW|c3nvci=> MXSyOVcxOTN5OB?=
MCF-7  M4D0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSxM|ExKM7:TR?= MUK3NkBp NY\oTXJXTE2VTx?= M1PjPYVvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w MUeyOVY3PzVzMB?=
MDA-MB-231  NVrBUHNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV76N|F3OS9zMDFOwG0> NXj2Om9XPzJiaB?= MXrEUXNQ NV[5epJT\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= NY\QfnBTOjV4Nke1NVA>
MDA-MB-231 NWfhNI1rTnWwY4Tpc44hSXO|YYm= NFPsSY0xNTRyINM1US=> NETY[3Q1NTJ2IHi= NYDJVJpDcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M{Lx[|I2PTh5M{K5
MCF-7 M{e5RWZ2dmO2aX;uJGF{e2G7 MV[wMVQxKML3TR?= MonXOE0zPCCq MV\lcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh M13MXVI2PTh5M{K5
MCF7-MX  MUnGeY5kfGmxbjDBd5NigQ>? Mn\1NE01OCEEtV2= MVu0MVI1KGh? M4\nT4VvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB? NFfkb4UzPTV6N{OyPS=>
MDA-MB-231 MmOzSpVv[3Srb36gRZN{[Xl? NULSWmk{OC12MDFCuW0> MYq0MVI1KGh? NHTQR3V{fGmvdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC= M2\xNFI2PTh5M{K5
A2780 M1zENGZ2dmO2aX;uJGF{e2G7 M1OzcVUwOTBxMUWg{txO NYi1RXFDPDhiaB?= MYrk[YNz\WG|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXuyOVQzPDh7OB?=
SKOV3  NXTXfZNLTnWwY4Tpc44hSXO|YYm= NYTDflNbPS9zMD:xOUDPxE1? MX20PEBp M2jVPIRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUiyOVQzPDh7OB?=
A2780 MWXGeY5kfGmxbjDBd5NigQ>? MkPtOU8yOC9zNTFOwG0> MXm0PEBp NFT2TotmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw NUDQRW93OjV2MkS4PVg>
SKOV3  MonhSpVv[3Srb36gRZN{[Xl? MXi1M|ExNzF3IN88US=> NX7WOHRbPDhiaB?= M1;McoVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5? MYOyOVQzPDh7OB?=
A2780 Ml3iSpVv[3Srb36gRZN{[Xl? M3;vNVUwOTBxMUWg{txO MXK0PEBp NV;Fb5JF\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu MYiyOVQzPDh7OB?=
SKOV3  M4Kxc2Z2dmO2aX;uJGF{e2G7 NInvdWY2NzFyL{G1JO69VQ>? NXnrelNTPDhiaB?= NEHK[XNl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6= NXvVeIVYOjV2MkS4PVg>
A2780 NWfETJNETnWwY4Tpc44hSXO|YYm= M{HwXFUwOTBxMUWg{txO MYWxJIg> NHnjOnlqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2WxZVI2PDJ2OEm4
SKOV3  M1frRWZ2dmO2aX;uJGF{e2G7 MVG1M|ExNzF3IN88US=> M3TJ[FEhcA>? NEH1bZhqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4LTRVI2PDJ2OEm4
HCT-15 NH\JbJVHfW6ldHnvckBCe3OjeR?= NEjaWHUyOC13MDFOwG0> MV:2MVM3KGh? MYPpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ MlnNNlUzOThyMki=
HT-29  MmLFSpVv[3Srb36gRZN{[Xl? MmPYNVAuPTBizszN NXnJe|R3Pi1|NjDo M4XIZ4lv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gR29ZNTJiaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= Mlq3NlUzOThyMki=
HSC3  MoHtR4VtdCCYaXHibYxqfHliQYPzZZk> MU[w5qCUPDBizszN Ml\iOFghcA>? MX3JR|UxRTJ3LkZCtVEvPzhyIN88US=> MV[yOVE6QDd6OR?=
HSC3  NVL6VoN7SXCxcITvd4l{KEG|c3H5 Mn7hNlUh|ryP NYj1fHRHPDhiaB?= MYLpcoR2[2W|IHHwc5B1d3Orcx?= NVK1NnM{OjVzOUi3PFk>
HSC3  M{TQVGZ2dmO2aX;uJGF{e2G7 NWrRZVNMOjVizszN MonmOFghcA>? NF75NXhmgGirYnn0d{B{cWewaX\pZ4FvfGy7IILl[JVk\WRibXnndoF1cW:wIHPvcYJqdmWmIIfpeIghS0WW MYKyOVE6QDd6OR?=
HSC3  NFPjdoVHfW6ldHnvckBCe3OjeR?= NIi2RoIzPSEQvF2= NVe5[HlEPDhiaB?= Mn;3bY5pcWKrdIOgTHNEOyClZXzsJIlvfmG|aX;uJINwdWKrbnXkJJdqfGhiQ1XU NGi4dHczPTF7OEe4PS=>
HSC3  NXT4dpJtTnWwY4Tpc44hSXO|YYm= MnfqNlUh|ryP MWe3NkBp NFTTfXhl\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA> Mn\nNlUyQTh5OEm=
201T  MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULYWVFMPzJiaB?= Ml\YSG1UVw>? M{DrbGlEPTB;NEiuOkDDvU1? M17aflI2ODV5OUSx
273T Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVW3NkBp M4Wxe2ROW09? NUC0UJp1UUN3ME24NE42KML3TR?= MojDNlUxPTd7NEG=
Hep-2 NF7JNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfNOFI{OzBxNUCvNVAxKM7:TR?= MnT6NVIwOjRxM{[vOFghcA>? NV;yeoVmTE2VTx?= NELqN3VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NIPwWZczPDl7OEW2OC=>
Hep-2 MkTRRZBweHSxc3nzJGF{e2G7 NUjQbHk{PTBizszN NG\we4MxNTR6IHi= MkDlSG1UVw>? MW\pcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= MlyyNlQ6QTh3NkS=
Hep-2 NFzJPY1HfW6ldHnvckBCe3OjeR?= M3vCPFUxKM7:TR?= Mnr0NE01QCCq NWHCW|BzTE2VTx?= NF;ibFJz\WS3Y3XzJJRp\SC2ZXzvcYVz[XOnIHHjeIl3cXS7IHfyZYR2[WyueR?= MlPmNlQ6QTh3NkS=
Hep-2 NITweHlHfW6ldHnvckBCe3OjeR?= Mny2OVAh|ryP M{O2U|AuPDhiaB?= Mk\XSG1UVw>? NGH3WIll\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>? MnzYNlQ6QTh3NkS=
SGC-7901 NXjy[HJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFniVIQyOC93MD:xNFAh|ryP MkjNNlQwPDhxN{KgbC=> NET0SZZFVVOR M3;SOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ Mn\1NlQ6QTJ7NUi=
MKN-45 NWDVV4hTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnKN21IOTBxNUCvNVAxKM7:TR?= NX3TOZhIOjRxNEivO|IhcA>? NFrJSolFVVOR M3PZfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M3nPdlI1QTl{OUW4
SGC-7901 M2S0R2Z2dmO2aX;uJGF{e2G7 MmLQNVAwPTBxMUCwJO69VQ>? MVS0PEBp MXvEUXNQ M{GxVoRwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MWWyOFk6Ojl3OB?=
MKN-45 NYPMcZdsTnWwY4Tpc44hSXO|YYm= M1jHUlExNzVyL{GwNEDPxE1? M3\vSFQ5KGh? NFfiUWZFVVOR M3fBU4Rwf26{ZXf1cIF1\XNidHjlJI1TVkFiZYjwdoV{e2mxbjDs[ZZmdHNib3[gR29ZNTJiYX7kJHBEVkFiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MlXNNlQ6QTJ7NUi=
C666-1 M3LJdmN6fG:2b4jpZ4l1gSCDc4PhfS=> M{C2Z|IxNThyIN88US=> NXLoR4lCOjRiaB?= M4nlOoRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> NYOzZYM1OjR6NUS4N|g>
CNE-1 MlHPR5l1d3SxeHnjbZR6KEG|c3H5 MnTvNlAuQDBizszN NFvsVHYzPCCq MnTk[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> NFjINZIzPDh3NEizPC=>
CNE-2 MlGyR5l1d3SxeHnjbZR6KEG|c3H5 MnXUNlAuQDBizszN M{HqWVI1KGh? NWnTXpZb\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? NXrtT5BKOjR6NUS4N|g>
C666-1 M1;GcmN6fG:2b4jpZ4l1gSCDc4PhfS=> Mnv4OlAh|ryP MkX0O{Bl MnPv[Y5p[W6lZYOgdoFlcWG2aX;uJIN6fG:2b4jpZ4l1gSC2aILveYdpKEORWD2yMYRmeGWwZHXueEBu[W6wZYK= NGrrW|MzPDh3NEizPC=>
CNE-1 NEK2S|REgXSxdH;4bYNqfHliQYPzZZk> NHW2Tos3OCEQvF2= NF\mT5U4KGR? M4DMSYVvcGGwY3XzJJJi\GmjdHnvckBkgXSxdH;4bYNqfHlidHjyc5VocCCFT2itNk1l\XCnbnTlcpQhdWGwbnXy NW[1Z4tmOjR6NUS4N|g>
SNU-1041 MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:4NE01OCEQvF2= M333UlQ5KGh? MU\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MknxNlQ3QTJ5MEO=
SNU-1041 M{PhdGZ2dmO2aX;uJGF{e2G7 MoT3NlAwOzBizszN NYXMOIRzPCCq M2HZc4lv\HWlZYOg[ZhxemW|c3nvckBw\sLiQ1jPVEwhT1KSN{lCpIFv\MLiWFLQNeKh[XRidHjlJHJPSSCuZY\lcOKh NYW1PINsOjR4OUK3NFM>
SNU-1041 NWi1dFM3TnWwY4Tpc44hSXO|YYm= MXGwMVQxKM7:TR?= MYq0JIg> NHzpR5F2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?= M3TldlI1Pjl{N{Cz
SGC-7901 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETqV|c2OC1zMkWg{txO MonBNlQwPDhxN{KgbC=> M1PxeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NULZWJVIOjR4N{[zPVQ>
SGC-7901 M1O2emFxd3C2b4Ppd{BCe3OjeR?= NFH2c|YyODBizszN MWG3NkBp MmS5bY5lfWOnczDhdI9xfG:|aYO= MV[yOFY4PjN7NB?=
SGC-7901 MXHGeY5kfGmxbjDBd5NigQ>? NEjxWlc4PS9zMECvNVI2KM7:TR?= M2LhO|I1NzR6L{eyJIg> NX\udlNxcW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI> NFnUbGUzPDZ5NkO5OC=>
LMeC  NIPtRlNHfW6ldHnvckBCe3OjeR?= NYficmsyOjBxNUCg{txO NHzOZ2M1QCCq NF\IcFll\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?= MUeyOFY2Pjd2Nh?=
CMeC-1 MXTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4\lc|IxNzVyIN88US=> Mme5OFghcA>? MXTpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MVWyOFY2Pjd2Nh?=
LMeC MWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGPVS|MzOC93MDFOwG0> NV\uO29MPDhiaB?= NHXsXY5qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M3H6[FI1PjV4N{S2
CMeC-1 M3HOZ2Z2dmO2aX;uJGF{e2G7 M3fZNFIxNzVyIN88US=> MkHUOFghcA>? MlzGbY5lfWOnczDHNU1UKGG{cnXzeC=> M1vFU|I1PjV4N{S2
LMeC NHq2VlFHfW6ldHnvckBCe3OjeR?= MYSyNE82OCEQvF2= MnXROFghcA>? NILHOo5qdmS3Y3XzJGcyNVNiYYLy[ZN1 MYKyOFY2Pjd2Nh?=
CMeC-1 NGO5XnpHfW6ldHnvckBCe3OjeR?= M4r2VlIxNzVyIN88US=> NGTPOGY1QCCq M3rtfIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{DBWVI1PjV4N{S2
LMeC MYfGeY5kfGmxbjDBd5NigQ>? MXmyNE82OCEQvF2= M{LPflQ5KGh? NYjhcVFM\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MX2yOFY2Pjd2Nh?=
CMeC-1 MYnGeY5kfGmxbjDBd5NigQ>? NXrMbmxWOjBxNUCg{txO Mn;wOFghcA>? NFXJTWFqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v NHvKe|kzPDZ3Nke0Oi=>
LMeC M3LvbGZ2dmO2aX;uJGF{e2G7 MWOyNE82OCEQvF2= MlPIOFghcA>? M1XnXYlv\HWlZYOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44> NIWxS2QzPDZ3Nke0Oi=>
OVCAR-3 NVLzcYhMS2WubDDWbYFjcWyrdImgRZN{[Xl? Mke3NVAhyrWP MUmxJIg> M{\wNIVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> MXmyOFUzODJ{Nx?=
OVCAR-3 M2PRU2Fxd3C2b4Ppd{BCe3OjeR?= NX3mc2lMOTBiwsXN NILn[HEyKGh? MX\wdo9ud3SnczDwZYNtcXSjeHXsMYlv\HWlZXSgZZBweHSxc3nzxsA> MViyOFUzODJ{Nx?=
OVCAR-3 M{GwNWZ2dmO2aX;uJGF{e2G7 NYDhT3diOTBiwsXN M2f6eFEhcA>? NXn1RYR1\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZT25xsA> M3fQZ|I1PTJyMkK3
OVCAR-3 NGnLbXVHfW6ldHnvckBCe3OjeR?= NGOzcmkyOCEEtV2= NHPXWJgyKGh? M{ezeIRwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> MUmyOFUzODJ{Nx?=
OVCAR-3 M2Lnd2Z2dmO2aX;uJGF{e2G7 NUfrXlR7OTBiwsXN M{nCdlEhcA>? NF\aXXZqdmirYnn0d{Bx[WOuaYThfIVtNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NIHEeI8zPDV{MEKyOy=>
CF33 NV;vOXhDTnWwY4Tpc44hSXO|YYm= NHq5cm0yODBizszN M1XRUlI1KGh? NIfxUFdqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= NXrY[ogxOjR3MEO3PFI>
CF33 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPENVAuOTByIN88US=> NWm1[np[OC12IHS= NH3NTWZqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIjHbIMzPDVyM{e4Ni=>
CF33 NUTNU5FCTnWwY4Tpc44hSXO|YYm= NHLic4cyOC1zMECg{txO NVK5bY5oPC1{NDDo NYroZWlN\GWlcnXhd4V{KGOnbHzzJIlvKHSqZTDTJJBp[XOnIHHu[EBqdmO{ZXHz[ZMh[2WubIOgbY4hTzBxR{GgZZJz\XO2 MkHONlQ2ODN5OEK=
LNCaP NGHEVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWyM|UwOTBizszN MVq5OkBp MUDpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XSxco\hd5RifGmw NH\COFYzPDJ7Nkm3PC=>
LNCaP MXzBdI9xfG:|aYOgRZN{[Xl? MXOyM|UwOTBizszN MkTlPVYhcA>? NEHlNnVqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=> MV6yOFI6Pjl5OB?=
PC-3  M1Hv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG5NE02OCEQvF2= NFjMSFg1QOLCiXi= MoTjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> Mk\6NlQyOjd6OEK=
PC-3  NXPlfXZ[S2WubDDWbYFjcWyrdImgRZN{[Xl? NVXKdXBVOC1zMECg{txO NWLySIZYPzJiaB?= NV7XTW9R\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NYjwO2RIOjRzMke4PFI>

... Click to View More Cell Line Experimental Data

In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
+ Expand

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
+ Expand
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT02845336 Recruiting Thyroid Eye Disease Johns Hopkins University January 31, 2017 Phase 2
NCT02054104 Suspended Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 27, 2014 Phase 1|Phase 2
NCT01143545 Completed Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 26, 2010 Phase 1
NCT01313429 Completed Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 23, 2011 Phase 1
NCT02160301 Suspended Post Operative Pain Control University of North Carolina, Chapel Hill November 2017 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID